2 weeks Ago By ABMN Staff
Artiva Biotherapeutics ( NASDAQ:ARTV – Get Free Report ) and Cardiol Therapeutics ( NASDAQ:CRDL – Get Free Report ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership. Analyst Recommendations This is a summary of recent recommendations and price targets for Artiva Biotherapeutics and Cardiol Therapeutics, as provided by MarketBeat. Artiva Biotherapeutics currently has a consensus target price of $21.
25, indicating a potential upside of 51.68%. Cardiol Therapeutics has a consensus target price of $8.
75, indicating a potential upside of 322.71%. Given Cardiol Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Artiva Biotherapeutics.
Profitability Institutional & Insider Ownership 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.
3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Earnings and Valuation This table compares Artiva Biotherapeutics and Cardiol Therapeutics”s revenue, earnings per share and valuation.
Artiva Biotherapeutics has higher revenue and earnings than Cardiol Therapeutics. Summary Cardiol Therapeutics beats Artiva Biotherapeutics on 6 of the 10 factors compared between the two stocks. About Artiva Biotherapeutics ( Get Free Report ) Artiva Biotherapeutics, Inc.
, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate.
The company was incorporated in 2019 and is headquartered in San Diego, California. About Cardiol Therapeutics ( Get Free Report ) Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases.
Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros.
The company was incorporated in 2017 and is headquartered in Oakville, Canada. Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
